London-based EyeBiotech comany secures $65M additional in series A round funding. a privately held clinical-stage ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases.
EyeBio will use the proceeds from the funding to accelerate the Company’s clinical development program and further build out its innovative retina pipeline.
New investors Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC joined the financing round, which included participation from existing investors SV Health Investors, Jeito Capital, Samsara Biocapital and MRL Ventures Fund.
Bernard Davitian, Partner at Omega Funds said, “We’re excited to be a part of the Series A extension along with Bain Capital Life Sciences and Vertex Ventures HC. We believe EyeBio’s innovative pipeline has the potential to greatly benefit patients with significant unmet medical needs leading to vision loss and blindness,”.
Christine Brennan, PhD, Managing Director at Vertex Ventures HC said, “EyeBio has a seasoned executive team committed to advancing new medicines leveraging novel biological mechanisms, which address remaining disease drivers such as persistent vascular leakage. EyeBio’s potential breakthrough solution presents tremendous potential in enhancing patient care and treatment outcomes for millions affected by sight-threatening disease,”.
David Guyer, MD, Chief Executive Officer and Co-Founder of EyeBio. “We are extremely excited about the potential of our pipeline and progress to date, The expansion of our Series A round in the current fundraising environment speaks to our investors’ enthusiasm for what the EyeBio team is accomplishing. We’re very fortunate to have the caliber of investors and board members that we do, and adding the resources and expertise of Bain Capital Life Sciences, Omega, and Vertex Ventures HC will enable us to deliver on the promise of EyeBio’s pipeline as quickly as possible.”
EyeBio said the completion of enrollment into the multiple ascending dose (MAD) portion of AMARONE, the Phase 1b/2a clinical trial of Restoret in patients with diabetic macular edema (DME) and neovascular age related macular degeneration (NVAMD).
About EyeBio (Eyebiotech Limited)
Eyebiotech Limited (EyeBio) is a clinical-stage, privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.
Founded in August 2021 by David Guyer, M.D., and Tony Adamis, M.D., EyeBio has a leadership team with a world-class track record in ophthalmology drug development.